Business Context and Reporting Period
Company: ARGENX SE
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of June 2026
Filing Date: June 3, 2026
Principal Executive Offices: Laarderhoogtweg 25, 1101 EB Amsterdam, the Netherlands
This filing serves as a Current Report incorporating by reference a press release issued on June 3, 2026 (Exhibit 99.1). The document confirms the registrant files annual reports under Form 20-F.
Key Financial Metrics
The provided filing text does not contain specific financial data. It acts as a cover document referencing an external press release. Consequently, the following metrics are not available in the source text:
- Revenue
- Profit
- Cash Flow
- Margins
- Debt
- Liquidity
Material Changes
The filing text does not provide details on material changes versus prior periods. The specific content of the referenced press release (Exhibit 99.1) is not included in the input text.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, guidance, outlook, risks, contingencies, or unusual items. These details are presumed to be within the attached Exhibit 99.1, which is not provided in the source text.
Investor Verification Checklist
- Review the full text of the press release dated June 3, 2026 (Exhibit 99.1) to understand the specific event triggering this filing.
- Verify if the press release contains updated clinical trial data, regulatory approvals, or commercial milestones, as these are typical drivers for ARGENX 6-K filings.
- Check subsequent filings for any financial impact resulting from the event described in the press release.